Literature DB >> 31685431

Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells.

Shaw M Akula1, Saverio Candido2, Stephen L Abrams1, Linda S Steelman1, Kvin Lertpiriyapong3, Lucio Cocco4, Giulia Ramazzotti4, Stefano Ratti4, Matilde Y Follo4, Alberto M Martelli4, Ramiro M Murata5, Pedro L Rosalen6, Bruno Bueno-Silva7, Severino Matias de Alencar8, Marco Falasca9, Giuseppe Montalto10, Melchiorre Cervello11, Monica Notarbartolo12, Agnieszka Gizak13, Dariusz Rakus13, Massimo Libra2, James A McCubrey14.   

Abstract

Improving the effects of chemotherapy and reducing the side effects are important goals in cancer research. Various approaches have been examined to enhance the effectiveness of chemotherapy. For example, signal transduction inhibitors or hormonal based approaches have been included with chemo- or radio-therapy. MIA-PaCa-2 and BxPC-3 pancreatic ductal adenocarcinoma (PDAC) cells both express the estrogen receptor (ER). The effects of β-estradiol on the growth of PDAC cells has not been examined yet the ER is expressed in PDAC cells. We have examined the effects of combining β-estradiol with chemotherapeutic drugs, signal transcription inhibitors, natural products and nutraceuticals on PDAC. In most cases, inclusion of β-estradiol with chemotherapeutic drugs increased chemosensitivity. These results indicate some approaches involving β-estradiol which may be used to increase the effectiveness of chemotherapeutic and other drugs on the growth of PDAC.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemotherapeutic drugs; Natural products; Nutraceuticals; Pancreatic cancer; β-Estradiol

Year:  2019        PMID: 31685431     DOI: 10.1016/j.jbior.2019.100672

Source DB:  PubMed          Journal:  Adv Biol Regul        ISSN: 2212-4926


  7 in total

Review 1.  CCAAT enhancer binding protein gamma (C/EBP-γ): An understudied transcription factor.

Authors:  Zachary Renfro; Bryan E White; Kimberly E Stephens
Journal:  Adv Biol Regul       Date:  2022-01-26

2.  Anti-Inflammatory Effects of (3S)-Vestitol on Peritoneal Macrophages.

Authors:  Bruno Bueno-Silva; Manuela Rocha Bueno; Dione Kawamoto; Renato C Casarin; João Marcos Spessoto Pingueiro; Severino Matias Alencar; Pedro Luiz Rosalen; Marcia Pinto Alves Mayer
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-29

3.  Study on the Potential Molecular Mechanism of Xihuang Pill in the Treatment of Pancreatic Cancer Based on Network Pharmacology and Bioinformatics.

Authors:  Jing Wang; Yaxing Zhang; Qiuyuan Wang; Luyao Wang; Peitong Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-11       Impact factor: 2.650

Review 4.  Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression.

Authors:  James A McCubrey; Li V Yang; Stephen L Abrams; Linda S Steelman; Matilde Y Follo; Lucio Cocco; Stefano Ratti; Alberto M Martelli; Giuseppa Augello; Melchiorre Cervello
Journal:  Cells       Date:  2022-07-09       Impact factor: 7.666

5.  Foreword for the special issue advances in COVID-19: Biology and clinic.

Authors:  James A McCubrey; Shaw M Akula; Bernard Payrastre
Journal:  Adv Biol Regul       Date:  2020-07-09

Review 6.  Inositol Polyphosphate-Based Compounds as Inhibitors of Phosphoinositide 3-Kinase-Dependent Signaling.

Authors:  Tania Maffucci; Marco Falasca
Journal:  Int J Mol Sci       Date:  2020-09-29       Impact factor: 5.923

7.  Pharmacologic Activation of the G Protein-Coupled Estrogen Receptor Inhibits Pancreatic Ductal Adenocarcinoma.

Authors:  Christopher A Natale; Jinyang Li; Jason R Pitarresi; Robert J Norgard; Tzvete Dentchev; Brian C Capell; John T Seykora; Ben Z Stanger; Todd W Ridky
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2020-05-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.